HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Personal-Care Firms Filing Waiver Requests En Masse As 1,4-Dioxane Deadline Looms In New York

Executive Summary

More than 800 waivers have been filed by companies including Procter & Gamble, L’Oréal and Coty with the first deadline fast-approaching for limiting 1,4-dioxane in personal-care products under a law enacted in New York in 2019.

You may also be interested in...



Cosmetics News In Brief: NY Slaps Limit On Cosmetic 1,4-Dioxane Content; J&J Talc Drama; IFF Merger

Suspected trace carcinogen 1,4-dioxane must be limited to 2 parts per million in personal cleansing products sold in New York after 31 December 2022, and 1 ppm one year later, under recently enacted legislation. More cosmetics news in brief.

P&G Leaders On Precision Digital Marketing, Why Less Can Be More

After two quarters of reduced marketing spending, P&G’s top executives used Investor Day 2022 to highlight the efficiencies and higher effectiveness of digital marketing compared with traditional. “We would be missing the point of productivity improvement if we only measure the effectiveness of our brand building by the dollars we spend,” CFO Andre Schulten said.

P&G Recalibrates ‘Irresistible Superiority’ As Economy, Competition Tighten

Procter & Gamble R&D aims to answer demand for "instant gratification" while the firm works to educate consumers on proper use of products for better experiences and improved brand loyalty, among other tactics discussed in its 17 November Investor Day presentation. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS153048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel